胸腺肽α1对80岁以上老年重症医院获得性肺炎患者的预后影响  

Effects of thymosin α1 on prognosis of very elderly patients with severe hosipital acquired pneumonia

作　　者：齐玉琴[1] 张兴虎[1] 万文辉[1] 吴宁[1] 黄方[1] 钱晓明[1] 

机构地区：[1]中国人民解放军南京军区老年病研究中心 中国人民解放军南京军区南京总医院干部病房一科,江苏省南京市210002

出　　处：《实用老年医学》2013年第3期215-217,共3页Practical Geriatrics

基　　金：中国人民解放军南京军区卫生部课题(08MA089)

摘　　要：目的 胸腺肽α1是一种功能确切的免疫增强剂。本文主要探讨胸腺肽α1对≥80岁老年人重症医院获得性肺炎患者外周血T细胞亚群指标的改变。方法 42例患者随机分成治疗组和对照组,对照组常规治疗(抗感染、营养支持、对症治疗)加安慰剂,治疗组在常规治疗的基础上,加用胸腺肽α1,观察2组治疗前后外周血T细胞亚群CD+3、CD+4、CD+8水平,CD+4/CD+8比值以及C-反应蛋白(CRP)、APACHEⅡ的变化。结果 治疗组在使用胸腺肽α114d后CD+3、CD+4百分率,CD+4/CD+8比值较用药前升高,且明显高于对照组,而CRP、APACHEⅡ评分显著下降。结论 ≥80岁老年人的基础免疫功能是低下的,而胸腺肽α1可提高重症肺炎患者机体的免疫功能,增强抗感染能力,改善患者预后。Objective To investigate the immunomodulatory effects of thymosin α1 on patients with severe pneumonia in the very elderly(≥80 years old).Methods Forty-two very elderly cases were randomly divided into treatment group and control group.Both groups were given conventional treatment(anti-infectives,nutritional support,and symptomatic treatment).Meanwhile treatment group was additionally treated with thymosin α1 for 14 days.In two groups,peripheral blood samples were collected before and after treatment,and the percents of CD+3,CD+4,CD+8,the ratio of CD+4/CD+8,the level of CRP in peripheral blood,and the score of APACHEⅡwere observed.Results After 14-day treatment of thymosin α1,the level of CRP and the score of APACHEⅡ decreased more significantly,and the percents of CD+3,CD+4,CD+8 and the ratio of CD+4/CD+8 incresed more significantly in treatment group than those in the control group.Conclusions The immune function is reduced in the very elderly,and thymosin α1 can improve ther immune function and enhance resistance to infection,and can improve those patients' outcomes.

关 键 词：胸腺肽Α 老年人 重症肺炎 免疫功能 

分 类 号：R563.1[医药卫生—呼吸系统]